F. Bădulescu *, Mihaela Dănciulescu *, V. Cârlig **, D. Lunguelscu ***, Luiza Pârvulescu ***, L. M. Pop *
* Conf. Dr. F. Bădulescu, Asist. Mihaela Dănciulescu, Asist. L.M. Pop – Facultatea de Medicină, Craiova, Disciplina de oncologie
** Conf. Dr. Valentin Cârlig – Facultatea de Medicină, Disciplina de Farmacologie
*** Dr. D. Lungztlescu, Dr. Luiza Pârvulescu – Clinica de Oncologie, Spitalul Clinic Nr. 1, Craiova
Abstract
The blockade of the androgen recepors in prostatic cancer represent an endocrinologic therapy directed to deprive the tumor cell from the primary and secondary levels of the androgens testicular and non- testicular. The aim of this study in the assessment of the effect of the androgen receptors blockade delivering Flucinom 12-30 months in dose 750 mg/day at 20 patients with advanced prostatic cancer. To assess the evolution of the neoplasm it were performed periodic: clinical examination, paraclinic and biologic assessments following dinamically the values of total and prostatic acid phosphatase and of alkaline phosphatase. The treatment with Flucinom has presented a good tolerance associated with lowered secondary effects, maintaining for a long period of time a good quality of life, manifested through lowering till dissapearance of the bony pain. The treatment with Flucinom hadn’t determined in all patients being in study the disease stability, ascertaining in some cases the continuity of the secondary bony evolution with the appearance of new metastasis. Although, the clin:cal efficiency of the treatment with Flucinom, even limited recommend it even as treatment of first line in patients with advanced prostatic cancer.